Hackensack, NJ – March 11, 2021 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021.
Third Quarter and Recent Highlights:
- Delivered record quarterly revenue of $10.8 million, an increase of 20% year over year
- Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $1.3 million
- Expanded Lumin Bioinformatics proprietary SaaS platform with proteomic module integration